PMC4377453_01
PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
CRIONM2015-471861.001.jpg
PMC4377453_03_CRIONM2015-471861.001.jpg
fig1
Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
PMC4377453_02
PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
CRIONM2015-471861.001.jpg
PMC4377453_03_CRIONM2015-471861.001.jpg
fig1
Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
PMC4377453_03
PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
CRIONM2015-471861.001.jpg
PMC4377453_03_CRIONM2015-471861.001.jpg
fig1
Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.
CRIONM2015-471861.002.jpg
PMC4377453_03_CRIONM2015-471861.002.jpg
fig2
CT findings of liver metastases and response to treatment are shown in Figure 2.
PMC4377453_04